The phase 1 clinical trial of APG333 is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers. It is expected to enroll approximately 32 ...

Cigarettes have been overtaken as the leading cause of illness and death in Australia, new government data reveals.

Vaping, initially perceived as a safer alternative to smoking, is now linked to lung damage. Studies reveal that vaping ...

You may think you can avoid getting sick, but in Georgia, respiratory virus season is already upon us. Even if you lead an ...

GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the ...

France: In non-COPD patients at high risk of extubation failure, prophylactic noninvasive ventilation (NIV) alternating with ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

Patients with COPD diagnosed in-hospital vs in a primary care setting tended to be older, men, and had a greater number of comorbidities.

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

Asthma, pneumonia and over 20 other conditions affecting the lungs and respiratory system are supported by PIP and ADP.

Growing population with respiratory diseases including chronic ailments is a key driver for the clinical demand ...

There are only a handful of days left until a backdated claim can be made for Pension Credit while also ensuring that the ...